TapImmune has entered in a definitive agreement to acquire Marker Therapeutics.
Clinicians in the not-too-distant future may have something new to offer women with breast cancer and ovarian cancer in whom initial therapy fails to yield a response.
TapImmune will be hosting an investor breakfast at the Blackstone hotel tomorrow, May 17th from 7:30am-10am. Come and meet with with Marker Co-Founders Juan Vera, M.D. and Ann Leen, Ph.D., and former President of the American Society for Gene and Cell Therapy Malcolm Brenner along with TapImmune Management.
TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform
It is great to welcome renowned thought leaders Dr. Cliona M. Rooney, Dr. Helen Heslop, current president of the American Society for Gene and Cell Therapy, and former President of ASGCT, Dr. Malcolm Brenner to the Scientific Advisory Board that will become effective in conjunction with the proposed merger between TapImmune and Marker Therapeutics, Inc.